The Eli Lilly & Co. logo at the company's Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024.Eli Lilly on Thursday said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than anticipated. The company expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025, according to fourth-quarter earnings slides on its website. Eli Lilly previousl ...